Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.59 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.54 |
| ▸ | ACLY | P53396 | 2/20 | 0.51 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330966 | 0.87 | PTPN1 (0.60) | HNF4AACMSDPTPN1ERN1ACLY | |
| SCHEMBL21857924 | 0.82 | KCNH2 (0.62) | PTPN1ACLYKCNH2 | |
| SCHEMBL4652841 | 0.82 | PTPN1 (0.51) | PTPN1ERN1ACLYKDM4EFTO | |
| SCHEMBL10024278 | 0.82 | KDM4E (0.54) | PTPN1ERN1PRSS12ACLYKDM4E | |
| SCHEMBL16256690 | 0.80 | PTPN1 (0.56) | PTPN1ERN1ACLYKDM4EFTO | |
| SCHEMBL1981933 | 0.80 | PTPN1 (0.59) | PTPN1ERN1ACLYKDM4EFTO | |
| SCHEMBL10024261 | 0.79 | PTPN1 (0.55) | PTPN1ERN1ACLYKDM4EFTO | |
| SCHEMBL6068103 | 0.78 | ERN1 (0.64) | ERN1KCNH2 | |
| SCHEMBL29744559 | 0.78 | ERN1 (0.64) | ERN1KCNH2 | |
| SCHEMBL29441950 | 0.78 | ACMSD (0.83) | HNF4AACMSDPTPN1XDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197418-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION | UNIV GRANADA (ES) | 2020-06-25 | — | — | US | disclosed |
| US-20200197418-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION | UNIV GRANADA (ES) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197418-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION | DOHH, OGDH, EGLN2 | HNF4A 4553/4885ACMSD 1084/4885PTPN1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.